Guillain-Barré syndrome (GBS) is a rare condition in which your immune system attacks the nerves outside your brain and spinal cord, causing weakness that typically starts in the legs and moves upward. It affects roughly 0.16 to 3 people per 100,000 each year and is usually triggered by an infection in the weeks before symptoms begin. Most people recover, but the condition can become a medical emergency when it progresses quickly.
How the Immune System Attacks the Nerves
GBS is an autoimmune disorder, meaning the body’s defenses mistakenly target its own tissue. In the most common form, called acute inflammatory demyelinating polyneuropathy (AIDP), immune cells attack the protective coating around peripheral nerves, the myelin sheath. Research published in Nature identified the specific culprits: memory immune cells that lock onto proteins found only on peripheral nerve myelin. These cells release inflammatory signals and molecules that directly damage nerve insulation, slowing or blocking the electrical signals that control movement and sensation.
A less common form, acute motor axonal neuropathy (AMAN), involves a different mechanism. Instead of attacking the myelin coating, antibodies target gangliosides, which are fat-like molecules on the nerve fiber itself. This form is strongly linked to a prior Campylobacter jejuni gut infection, and the antibodies form because the bacterial surface closely resembles the nerve’s surface, a process called molecular mimicry. There is also a variant called AMSAN that damages both motor and sensory nerve fibers, which tends to recover more slowly.
Common Triggers
Most cases of GBS follow an infection by one to six weeks. Campylobacter, a bacterium that causes food poisoning, is one of the most common triggers in the United States. Viral infections are also well-established triggers, including influenza, cytomegalovirus, Epstein-Barr virus, and Zika virus. In many cases, the triggering infection was mild enough that a person may not have sought medical attention for it.
Vaccines have drawn attention as a possible trigger, largely because of an event in 1976 when a swine flu vaccination campaign led to roughly one additional GBS case per 100,000 vaccinated people. Modern seasonal flu vaccines carry a much smaller signal, in the range of one to two extra cases per million doses when any increase is detected at all. The CDC notes that getting the flu itself is more likely to trigger GBS than getting the flu vaccine.
Early Symptoms and How They Progress
Weakness and tingling in the feet and hands are usually the first signs. The pattern is often described as “ascending” because it starts in the lower extremities and moves upward into the trunk and arms, though some people notice symptoms in the arms or face first. The weakness can range from mild difficulty walking to complete paralysis. Most people reach their maximum level of weakness within two weeks of the first symptoms, which helps distinguish GBS from slower-developing nerve conditions.
Other common symptoms include pain (often deep and aching in the legs and back), difficulty with eye movements or facial muscles, and problems with blood pressure or heart rate. A variant called Miller Fisher syndrome is unusual in that it primarily affects the eyes, causes poor coordination, and weakens reflexes rather than following the typical ascending pattern.
When GBS Becomes an Emergency
About 30% of people with GBS lose the ability to breathe on their own and need mechanical ventilation. Of those who require a ventilator, roughly 75% develop pneumonia as a complication. This is the main reason GBS patients are closely monitored in the hospital, often in an intensive care unit. Breathing capacity is checked frequently because the muscles that expand the lungs can weaken rapidly over hours.
How GBS Is Diagnosed
Diagnosis relies on the clinical pattern of ascending weakness combined with two key tests. The first is a spinal tap, where a sample of cerebrospinal fluid is drawn from the lower back. A hallmark finding is elevated protein levels with a normal white blood cell count. This combination is characteristic enough that it has its own name in clinical medicine. Protein levels tend to be higher the longer the illness has been progressing and are especially elevated in the demyelinating form of GBS.
The second test is nerve conduction studies, which measure how fast and how well electrical signals travel through your nerves. These studies help doctors classify which variant of GBS is present, whether the damage is to the myelin coating or the nerve fiber itself, which influences the expected recovery timeline.
Treatment Options
Two main treatments can shorten the course of GBS and reduce its severity. Plasma exchange filters the blood to remove the harmful antibodies attacking the nerves. It was the first proven therapy, established in the mid-1980s. The second option is intravenous immunoglobulin, a concentrated dose of donated antibodies that appears to calm the immune response, in part by promoting the growth of regulatory immune cells that suppress the autoimmune attack.
Both treatments are considered similarly effective. They work best when started early. Neither is a cure in the traditional sense; they reduce the severity and duration of the immune assault, giving the nerves a better chance to recover. Combining the two treatments has not been shown to provide additional benefit over either one alone. Supportive care in the hospital, including physical therapy to maintain joint flexibility and prevent blood clots, is equally important during the acute phase.
Recovery and Long-Term Outlook
Recovery from GBS is slow. Nerves regenerate at roughly an inch per month, so regaining function can take months to years depending on how much damage occurred. Follow-up studies tracking patients three to five years after onset found that 64% achieved full functional recovery, 27% were left with minor deficits like lingering numbness or mild weakness, and about 9% continued to need assistance with daily activities.
Fatigue is one of the most persistent complaints, often lasting well beyond the point where strength has returned. Many people describe it as a deep, whole-body exhaustion that is disproportionate to their activity level. Pain, particularly nerve pain in the extremities, can also linger for months or years. Physical rehabilitation plays a major role in recovery. Early, gentle range-of-motion exercises transition to strengthening work as nerve function returns, and the pace is tailored to what each person can tolerate without overloading recovering nerves.
The axonal variants, AMAN and especially AMSAN, tend to recover more slowly than the demyelinating form because damage to the nerve fiber itself is harder to repair than damage to its insulating sheath. Age, the speed of symptom onset, and the severity of weakness at its peak are the strongest predictors of long-term outcome.